A Phase II Clinical Trial of Reduced Port Totally Laparoscopic Distal Gastrectomy With D2 Lymph Node Dissection
Primary Purpose
Gastric Cancer
Status
Unknown status
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
reduced port laparoscopic distal gastrectomy
Sponsored by
About this trial
This is an interventional treatment trial for Gastric Cancer focused on measuring gastric cancer, laparoscope
Eligibility Criteria
Inclusion Criteria:
- histologically confirmed adenocarcinoma of the stomach
- Eastern Cooperative Oncology Group Eastern Cooperative Oncology Group performance status 0-1,
- signed informed consent
- location of the primary tumor in the antrum, angle and lower body
- no evidence of distant metastasis or invasion to adjacent organs or serosal infiltration
Exclusion Criteria:
- metastatic disease
- previous history of malignancy in any organ
- any co-morbidity obviating major surgery
Sites / Locations
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
reduced port
Arm Description
gastric cancer patients go through reduced port laparoscopic distal gastrectomy with D2 lymph node dissection
Outcomes
Primary Outcome Measures
Compliance rate (Japanese Research Society of Gastric Cancer (JRSGC) lymph node grouping)
Compliance rate : Cases with no more than one missing lymph node station according to the Japanese Research Society of Gastric Cancer (JRSGC) lymph node grouping
Secondary Outcome Measures
Full Information
NCT ID
NCT02311595
First Posted
December 4, 2014
Last Updated
December 5, 2014
Sponsor
Samsung Medical Center
1. Study Identification
Unique Protocol Identification Number
NCT02311595
Brief Title
A Phase II Clinical Trial of Reduced Port Totally Laparoscopic Distal Gastrectomy With D2 Lymph Node Dissection
Official Title
A Phase II Clinical Trial of Reduced Port Totally Laparoscopic Distal Gastrectomy With D2 Lymph Node Dissection for Gastric Cancer Patients
Study Type
Interventional
2. Study Status
Record Verification Date
December 2014
Overall Recruitment Status
Unknown status
Study Start Date
December 2014 (undefined)
Primary Completion Date
March 2015 (Anticipated)
Study Completion Date
March 2015 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Samsung Medical Center
4. Oversight
5. Study Description
Brief Summary
The purpose of this study is to determine if reduced port totally laparoscopic distal gastrectomy with complete D2 lymph node dissection for gastric cancer is safe and oncological feasible.
67 patients with gastric cancer with preoperative staging from T1 to T3 will undergo reduced port totally laparoscopic distal gastrectomy.
The primary end point of this study is to measure compliance rate with pathology report and compare with previous compliance rate data.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Gastric Cancer
Keywords
gastric cancer, laparoscope
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
67 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
reduced port
Arm Type
Experimental
Arm Description
gastric cancer patients go through reduced port laparoscopic distal gastrectomy with D2 lymph node dissection
Intervention Type
Procedure
Intervention Name(s)
reduced port laparoscopic distal gastrectomy
Primary Outcome Measure Information:
Title
Compliance rate (Japanese Research Society of Gastric Cancer (JRSGC) lymph node grouping)
Description
Compliance rate : Cases with no more than one missing lymph node station according to the Japanese Research Society of Gastric Cancer (JRSGC) lymph node grouping
Time Frame
1 month after enrollment of the patients
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
histologically confirmed adenocarcinoma of the stomach
Eastern Cooperative Oncology Group Eastern Cooperative Oncology Group performance status 0-1,
signed informed consent
location of the primary tumor in the antrum, angle and lower body
no evidence of distant metastasis or invasion to adjacent organs or serosal infiltration
Exclusion Criteria:
metastatic disease
previous history of malignancy in any organ
any co-morbidity obviating major surgery
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Jun Ho Lee, M.D. ph.D
Phone
82-2-3410-3463
Email
gsjunholee@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Jieun Kim, M.D.
Phone
82-2-3410-1735
Email
wldmsld.kim@samsung.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jun Ho Lee, M.D. ph.D
Organizational Affiliation
Samsung Medical Center
Official's Role
Study Chair
12. IPD Sharing Statement
Citations:
PubMed Identifier
17705092
Citation
Lee JH, Kim YW, Ryu KW, Lee JR, Kim CG, Choi IJ, Kook MC, Nam BH, Bae JM. A phase-II clinical trial of laparoscopy-assisted distal gastrectomy with D2 lymph node dissection for gastric cancer patients. Ann Surg Oncol. 2007 Nov;14(11):3148-53. doi: 10.1245/s10434-007-9446-0. Epub 2007 Aug 20.
Results Reference
background
PubMed Identifier
25227307
Citation
Kim SM, Lee JH, Lee SH, Ha MH, Seo JE, Kim JE, Choi MG, Sohn TS, Bae JM, Kim S. Techniques of reduced PRT laparoscopy-assisted distal gastrectomy (duet LADG). Ann Surg Oncol. 2015 Mar;22(3):793. doi: 10.1245/s10434-014-4087-6. Epub 2014 Sep 17.
Results Reference
background
PubMed Identifier
10089184
Citation
Bonenkamp JJ, Hermans J, Sasako M, van de Velde CJ, Welvaart K, Songun I, Meyer S, Plukker JT, Van Elk P, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H; Dutch Gastric Cancer Group. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999 Mar 25;340(12):908-14. doi: 10.1056/NEJM199903253401202.
Results Reference
background
Learn more about this trial
A Phase II Clinical Trial of Reduced Port Totally Laparoscopic Distal Gastrectomy With D2 Lymph Node Dissection
We'll reach out to this number within 24 hrs